Hypertension, antihypertensive medications, and risk of incident primary hyperparathyroidism

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 6, 2015, Pages 2396-2404

  Vaidya, Anand ^a,d,f   Curhan, Gary C ^b,c,d,f   Paik, Julie M ^b,c,d,f   Kronenberg, Henry ^e,f   Taylor, Eric N ^c,d,g  

^a Division of Endocrinology Diabetes and Hypertension   (United States)

^b Renal Division   (United States)

^c CHANNING LABORATORY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Endocrine Unit   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g MAINE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE;

ADULT; AGE; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DIETARY INTAKE; DRUG USE; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDICAL RECORD; MENOPAUSE; NATIONAL HEALTH SERVICE; NUTRITIONAL ASSESSMENT; PHYSICAL ACTIVITY; POSTMENOPAUSE; PREMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK ASSESSMENT; SMOKING; COMPLICATION; HYPERPARATHYROIDISM, PRIMARY; MIDDLE AGED; NURSE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; ANTIHYPERTENSIVE AGENTS; FEMALE; FUROSEMIDE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDIES; MIDDLE AGED; NURSES; RISK FACTORS; UNITED STATES;

EID: 84930805343     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-1619     Document Type: Article

References (56)

1. Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98:1122-1129.
2. Wermers RA, Khosla S, Atkinson EJ, Hodgson SF, O'Fallon WM, Melton LJ 3rd. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med. 1997;126:433-440.
3. Adami S, Marcocci C, Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res. 2002;17(Suppl 2): N18-N23.
4. Yu N, Donnan PT, Murphy MJ, Leese GP. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol (Oxf). 2009;71:485-493.
5. Fraser WD. Hyperparathyroidism. Lancet. 2009;374:145-158.
6. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008;93:3462-3470.
7. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341:1249-1255.
8. Jorde R,Bønaa KH, Sundsfjord J. Primary hyperparathyroidism detected in a health screening. The Trømsø study. J Clin Epidemiol. 2000;53:1164-1169.
9. Lundgren E, Hagström EG, Lundin J, et al. Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago. World J Surg. 2002;26:931-936.
10. Paik JM, Curhan GC, Taylor EN. Calcium intake and risk of primary hyperparathyroidism in women: prospective cohort study. BMJ. 2012;345:e6390.
11. Dent CE, Hartland BV, Hicks J, Sykes ED. Calcium intake in patients with primary hyperparathyroidism. Lancet. 1961;2:336-338.
12. Insogna KL, Mitnick ME, Stewart AF, Burtis WJ, Mallette LE, Broadus AE. Sensitivity of the parathyroid hormone-1,25-dihydroxyvitamin D axis to variations in calcium intake in patients with primary hyperparathyroidism. N Engl J Med. 1985;313:1126-1130.
13. Jorde R, Szumlas K, Haug E, Sundsfjord J. The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake. Eur J Nutr. 2002;41:258-263.
14. Brown J, de Boer IH, Robinson-Cohen C, et al. Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab. 2015;100:490-499.
15. Zhao G, Ford ES, Li C, Kris-Etherton PM, Etherton TD, Balluz LS. Independent associations of serum concentrations of 25-hydroxyvitamin D and parathyroid hormone with blood pressure among US adults. J Hypertens. 2010;28:1821-1828.
16. Blondon M, Sachs M, Hoofnagle AN, et al. 25-Hydroxyvitamin D and parathyroid hormone are not associated with carotid intimamedia thickness or plaque in the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2013;33:2639-2645.
17. van Ballegooijen AJ, Kestenbaum B, Sachs MC, et al. Association of 25-hydroxyvitamin D and parathyroid hormone with incident hypertension: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2014;63:1214-1222.
18. van Ballegooijen AJ, Reinders I, Visser M, et al. Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: the Hoorn study. J Clin Endocrinol Metab. 2013;98:E638-E645.
19. Pilz S, Tomaschitz A, Drechsler C, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J. 2010;31:1591-1598.
20. van Ballegooijen AJ, Visser M, Cotch MF, et al. Serum vitamin D and parathyroid hormone in relation to cardiac structure and function: the ICELAND-MI substudy of AGES-Reykjavik. J Clin Endocrinol Metab. 2013;98:2544-2552.
21. van Ballegooijen AJ, Visser M, Kestenbaum B, et al. Relation of vitamin D and parathyroid hormone to cardiac biomarkers and to left ventricular mass (from the Cardiovascular Health Study). Am J Cardiol. 2013;111:418-424.
22. Rejnmark L, Vestergaard P, Pedersen AR, Heickendorff L, Andreasen F, Mosekilde L. Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded Latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest. 2003;33:41-50.
23. Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L. Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J Intern Med. 2001;250:144-153.
24. Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L. Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res. 2006; 21:163-170.
25. Isakova T, Anderson CA, Leonard MB, et al. Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrol Dial Transplant. 2011;26:1258-1265.
26. Corapi KM, McMahon GM, Wenger JB, Seifter JL, Bhan I. Association of loop diuretic use with higher parathyroid hormone levels in patients with normal renal function. JAMA Intern Med. 2015; 175:137-138.
27. Brown JM, Williams JS, Luther JM, et al. Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone. Hypertension. 2014; 63:273-280.
28. Pilz S, Kienreich K, Drechsler C, et al. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab. 2012; 97:E75-E79.
29. Tomaschitz A, Pilz S. Interplay between sodium and calcium regulatory hormones: a clinically relevant research field. Hypertension. 2014;63:212-214.
30. Tomaschitz A, Ritz E, Pieske B, et al. Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. Cardiovasc Res. 2012;94:10-19.
31. 2+ signals in normal human parathyroid cells. J Physiol Sci. 2013;63:235-240.
32. Zaheer S, Brown JM, Allison MA, et al. Diuretic and calcium-channel blocker use and parathyroid hormone levels: the Multi-Ethnic Study of Atherosclerosis [SAT-248]. In: ENDO 2015. The Endocrine Society's 97th Annual Meeting and Expo, March 5- 8, 2015; San Diego, CA. Washington, DC: Endocrine Society; 2015.
33. Colditz GA, Martin P, Stampfer MJ, et al. Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol. 1986;123:894-900.
34. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151:1141-1147.
35. Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB, Willett WC. Validity of self-reported waist and hip circumferences in men and women. Epidemiology. 1990;1:466-473.
36. Wolf AM, Hunter DJ, Colditz GA, et al. Reproducibility and validity of a self-administered physical activity questionnaire. Int J Epidemiol. 1994;23:991-999.
37. Colditz GA, Stampfer MJ, Willett WC, et al. Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol. 1987;126:319-325.
38. Salvini S, Hunter DJ, Sampson L, et al. Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption. Int J Epidemiol. 1989;18:858-867.
39. Willett WC, Sampson L, Stampfer MJ, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 1985;122:51-65.
40. Fliser D, Franek E, Fode P, et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant. 1997;12:933-938.
41. Hagström E, Hellman P, Larsson TE, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009;119:2765-2771.
42. Hagström E, Ingelsson E, Sundström J, et al. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail. 2010;12:1186-1192.
43. Jorde R, Sundsfjord J, Haug E, Bonaa KH. Relation between low calcium intake, parathyroid hormone, and blood pressure. Hypertension. 2000;35:1154-1159.
44. Morfis L, Smerdely P, Howes LG. Relationship between serum parathyroid hormone levels in the elderly and 24 h ambulatory blood pressures. J Hypertens. 1997;15:1271-1276.
45. 3 ratio in a general population. Am J Hypertens. 2011;24:102-109.
46. Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90:3326-3330.
47. Brown JM, Vaidya A. Interactions between adrenal-regulatory and calcium-regulatory hormones in human health. Curr Opin Endocrinol Diabetes Obes. 2014;21:193-201.
48. Tomaschitz A, Ritz E, Pieske B, et al. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism. 2014;63:20-31.
49. Chamarthi B, Williams JS, Williams GH. A mechanism for saltsensitive hypertension: abnormal dietary sodium-mediated vascular response to angiotensin-II. J Hypertens. 2010;28:1020-1026.
50. Carbone LD, Johnson KC, Bush AJ, et al. Loop diuretic use and fracture in postmenopausal women: findings from the Women's Health Initiative. Arch Intern Med. 2009;169:132-140.
51. LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000;133:516-526.
52. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.
53. Ott SM, LaCroix AZ, Scholes D, Ichikawa LE, Wu K. Effects of three years of low-dose thiazides on mineral metabolism in healthy elderly persons. Osteoporos Int. 2008;19:1315-1322.
54. Bertrand KA, Giovannucci E, Liu Y, et al. Determinants of plasma 25-hydroxyvitamin D and development of prediction models in three US cohorts. Br J Nutr. 2012;108:1889-1896.
55. Rao DS, Honasoge M, Divine GW, et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab. 2000;85:1054-1058.
56. Rao DS, Agarwal G, Talpos GB, et al. Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res. 2002;17(Suppl 2):N75-N80.